NO951006D0 - Farmasöytiske formuleringer av interleukin-1-inhibitorer - Google Patents
Farmasöytiske formuleringer av interleukin-1-inhibitorerInfo
- Publication number
- NO951006D0 NO951006D0 NO951006A NO951006A NO951006D0 NO 951006 D0 NO951006 D0 NO 951006D0 NO 951006 A NO951006 A NO 951006A NO 951006 A NO951006 A NO 951006A NO 951006 D0 NO951006 D0 NO 951006D0
- Authority
- NO
- Norway
- Prior art keywords
- inhibitors
- interleukin
- pharmaceutical formulations
- pharmaceutical compositions
- viscosity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94700692A | 1992-09-17 | 1992-09-17 | |
| PCT/US1993/008802 WO1994006457A1 (en) | 1992-09-17 | 1993-09-17 | Pharmaceutical formulations of interleukin-1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO951006L NO951006L (no) | 1995-03-15 |
| NO951006D0 true NO951006D0 (no) | 1995-03-15 |
| NO321453B1 NO321453B1 (no) | 2006-05-15 |
Family
ID=25485348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19951006A NO321453B1 (no) | 1992-09-17 | 1995-03-15 | Farmasoytiske formuleringer av interleukin-1-inhibitorer |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0661992B1 (no) |
| JP (1) | JP3626755B2 (no) |
| KR (1) | KR950703358A (no) |
| AT (1) | ATE257389T1 (no) |
| AU (1) | AU675969B2 (no) |
| CA (1) | CA2141953C (no) |
| CZ (1) | CZ291261B6 (no) |
| DE (1) | DE69333378T2 (no) |
| DK (1) | DK0661992T3 (no) |
| ES (1) | ES2213744T3 (no) |
| FI (1) | FI951250A (no) |
| HU (1) | HU219445B (no) |
| NO (1) | NO321453B1 (no) |
| NZ (1) | NZ256328A (no) |
| PL (1) | PL175705B1 (no) |
| PT (1) | PT661992E (no) |
| RO (1) | RO113528B1 (no) |
| RU (1) | RU2126262C1 (no) |
| WO (1) | WO1994006457A1 (no) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
| US6159460A (en) * | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| ATE508733T1 (de) * | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| EP2002846B1 (en) | 1996-12-06 | 2017-01-25 | Amgen Inc. | Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6013253A (en) * | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| DE122010000047I1 (de) | 2001-06-26 | 2011-05-05 | Amgen Fremont Inc | Antikörper gegen opgl |
| JP4610154B2 (ja) * | 2002-05-30 | 2011-01-12 | 大塚製薬株式会社 | 注射用製剤 |
| CN100471871C (zh) | 2002-09-06 | 2009-03-25 | 安姆根有限公司 | 治疗性人抗－il－1r1单克隆抗体 |
| EP1729810B1 (en) * | 2004-04-02 | 2018-08-15 | Swedish Orphan Biovitrum AB (Publ) | Methods of reducing aggregation of il-1ra |
| TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| JP2008120722A (ja) * | 2006-11-10 | 2008-05-29 | Benesis Corp | 生物由来製品の偽薬 |
| WO2009062339A1 (en) | 2007-11-14 | 2009-05-22 | General Regeneratives, Ltd. | Methods of using interleukin-1 receptor antagonist as a myeloprotective agent |
| US20110098267A1 (en) * | 2008-02-07 | 2011-04-28 | Synta Pharmaceuticals Corporation | Topical formulations for the treatment of psoriasis |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| CN101690801B (zh) | 2009-10-26 | 2012-08-01 | 上海交通大学 | 白细胞介素-1受体拮抗剂的用途及其药物组合物 |
| EP2501685A1 (en) | 2009-11-16 | 2012-09-26 | Mellitech | [1,5]-diazocin derivatives |
| PL3470421T3 (pl) | 2010-07-29 | 2023-10-23 | Buzzard Pharmaceuticals AB | Chimeryczne antagonisty receptora il-1 typu i |
| WO2012078101A1 (en) * | 2010-12-07 | 2012-06-14 | Swedish Orphan Biovitrum Ab (Publ) | Method for the treatment of il-1 mediated diseases |
| HUE029809T2 (en) * | 2011-02-11 | 2017-03-28 | Swedish Orphan Biovitrum Ab (Publ) | Pharmaceutical preparations containing citrate-free anakinra |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| RU2014107743A (ru) * | 2011-07-29 | 2015-09-10 | Илэвэн Байотерапьютикс, Инк. | Очищенные белки |
| EP2968468B1 (en) | 2013-03-13 | 2021-07-14 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
| WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| US10751426B2 (en) | 2015-10-30 | 2020-08-25 | Bonac Corporation | Composition stably containing single-stranded nucleic acid molecule that suppresses expression of TGF-β1 gene |
| US10041044B2 (en) | 2016-07-29 | 2018-08-07 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
| WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5416568B2 (no) * | 1972-09-29 | 1979-06-23 | ||
| JPS537491B2 (no) * | 1972-09-30 | 1978-03-18 | ||
| WO1992012724A1 (en) * | 1991-01-17 | 1992-08-06 | The Upjohn Company | Method of preventing and treating insulin dependent diabetes mellitus |
-
1993
- 1993-09-17 RO RO95-00540A patent/RO113528B1/ro unknown
- 1993-09-17 DK DK93921651T patent/DK0661992T3/da active
- 1993-09-17 ES ES93921651T patent/ES2213744T3/es not_active Expired - Lifetime
- 1993-09-17 EP EP93921651A patent/EP0661992B1/en not_active Expired - Lifetime
- 1993-09-17 CZ CZ1995643A patent/CZ291261B6/cs not_active IP Right Cessation
- 1993-09-17 NZ NZ256328A patent/NZ256328A/en not_active IP Right Cessation
- 1993-09-17 HU HU9500790A patent/HU219445B/hu unknown
- 1993-09-17 RU RU95109908A patent/RU2126262C1/ru active
- 1993-09-17 AT AT93921651T patent/ATE257389T1/de active
- 1993-09-17 JP JP50833894A patent/JP3626755B2/ja not_active Expired - Lifetime
- 1993-09-17 AU AU49276/93A patent/AU675969B2/en not_active Expired
- 1993-09-17 KR KR1019950701028A patent/KR950703358A/ko not_active Application Discontinuation
- 1993-09-17 DE DE69333378T patent/DE69333378T2/de not_active Expired - Lifetime
- 1993-09-17 WO PCT/US1993/008802 patent/WO1994006457A1/en active IP Right Grant
- 1993-09-17 CA CA002141953A patent/CA2141953C/en not_active Expired - Lifetime
- 1993-09-17 PT PT93921651T patent/PT661992E/pt unknown
- 1993-09-17 PL PL93308543A patent/PL175705B1/pl unknown
-
1995
- 1995-03-15 NO NO19951006A patent/NO321453B1/no not_active IP Right Cessation
- 1995-03-16 FI FI951250A patent/FI951250A/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ291261B6 (cs) | 2003-01-15 |
| NO321453B1 (no) | 2006-05-15 |
| AU675969B2 (en) | 1997-02-27 |
| ATE257389T1 (de) | 2004-01-15 |
| KR950703358A (ko) | 1995-09-20 |
| JPH08504755A (ja) | 1996-05-21 |
| CA2141953A1 (en) | 1994-03-31 |
| FI951250A0 (fi) | 1995-03-16 |
| FI951250A (fi) | 1995-03-16 |
| DE69333378D1 (de) | 2004-02-12 |
| HU219445B (hu) | 2001-04-28 |
| EP0661992A1 (en) | 1995-07-12 |
| JP3626755B2 (ja) | 2005-03-09 |
| NO951006L (no) | 1995-03-15 |
| PL175705B1 (pl) | 1999-01-29 |
| EP0661992B1 (en) | 2004-01-07 |
| CA2141953C (en) | 2008-04-08 |
| AU4927693A (en) | 1994-04-12 |
| RO113528B1 (ro) | 1998-08-28 |
| DK0661992T3 (da) | 2004-04-05 |
| HUT71679A (en) | 1996-01-29 |
| RU2126262C1 (ru) | 1999-02-20 |
| PT661992E (pt) | 2004-05-31 |
| CZ64395A3 (en) | 1995-10-18 |
| WO1994006457A1 (en) | 1994-03-31 |
| NZ256328A (en) | 1997-06-24 |
| PL308543A1 (en) | 1995-08-21 |
| ES2213744T3 (es) | 2004-09-01 |
| HU9500790D0 (en) | 1995-05-29 |
| DE69333378T2 (de) | 2004-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO951006D0 (no) | Farmasöytiske formuleringer av interleukin-1-inhibitorer | |
| SE7903186L (sv) | Cerebralverksamt medel | |
| RU95106996A (ru) | Сульфонилалканоиламино-гидроксиэтиламино-сульфонамидные соединения, фармацевтические композиции и способы лечения и ингибирования ретровирусных протеаз | |
| RU95106823A (ru) | Сукциноиламиногидроксиэтиламиносульфонамиды, фармацевтическая композиция, способ ингибирования ретровирусной протеазы, способ лечения ретровирусной инфекции способ лечения спида | |
| ATE324907T1 (de) | Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen | |
| FI925787A (fi) | Proteolytiska enzymers sackarinderivatinhibitorer | |
| DE69710065T2 (de) | Androsten-derivate | |
| ATE245977T1 (de) | Therapeutische substituierte guanidine | |
| SE9201628D0 (sv) | Pharmaceutical composition | |
| ATE147981T1 (de) | Verabreichung von lamotrigin zur behandlung von neuro-aids | |
| EA199900876A1 (ru) | Фармацевтические композиции против кашля | |
| FI935777A0 (fi) | Inhibitorer foer HIV-proteas anvaendbara vid behandling av AIDS | |
| FI923752A0 (fi) | Benso(f)kinolinoner. | |
| IT1196307B (it) | Formulazioni farmaceutiche acquose di piroxicam monoidrato | |
| IL139318A (en) | Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same | |
| DE69418035T2 (de) | Hiv-proteaseinhibitoren | |
| ES2096874T3 (es) | Inhibidor de la proteasa de hiv util para el tratamiento del sida. | |
| MX9204815A (es) | Hexahidrobenzo[f]quinolinonas y formulacion farmaceutica que las comprende. | |
| DK1100463T3 (da) | Injicerbare formuleringer indeholdende ramoplanin | |
| RU95106624A (ru) | Гидроксиэтиламиносульфонамиды, промежуточные соединения, фармацевтическая композиция, способ ингибирования ретровирусных протеаз, способ лечения ретровирусных инфекций, способ лечения спида | |
| GEP19991586B (en) | Pharmaceutical Formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |